Crescendo Biologics has announced that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.
Theodora joined the company in October 2016 and has worked in close partnership with Peter in the day-to-day running ever since.
She was central to the recent $70 million fund raising and has had responsibility not only for finance and operations but also, more recently, for business development, as well as having established strong relationships with Crescendo’s development partners.
Before joining the Company, she held both industry and corporate finance roles with private and listed biotech SMEs including PsiOxus Therapeutics Ltd, MISSION Therapeutics Ltd, OrthoMimetics Ltd and Cytomyx Holdings plc. Prior to this, Theodora qualified as a Chartered Accountant with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.
Kevin Johnson, non-executive chairman of Crescendo Biologics, said: “Theodora has been a driving force for the Company since she joined. Not only has she made a significant difference to the day-to-day running of the Company, but she has been a major contributor to the corporate, business development and operational strategies.
“The decision to appoint Theodora to succeed Peter was a straightforward and a unanimous one because of her in-depth knowledge of the business and industry as a whole. She has worked tirelessly to build the business so far and she has exciting ambitions for the Company in the longer term.”
